156 related articles for article (PubMed ID: 37067945)
1. Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group.
Al Tabaa Y; Casasnovas RO; Baillet C; Bachy E; Nicolas-Virelizier E; Schiano De Colella JM; Bailly C; Kanoun S; Guidez S; Gyan E; Gressin R; Morineau N; Ysebaert L; Le Gouill S; Tilly H; Houot R; Morschhauser F; Cartron G; Herbaux C
Blood Adv; 2023 Jul; 7(14):3735-3738. PubMed ID: 37067945
[No Abstract] [Full Text] [Related]
2. Al Tabaa Y, Casasnovas RO, Baillet C, et al. Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group. Blood Adv. 2023;7(14):3735-3738.
Blood Adv; 2024 Jun; 8(12):3225. PubMed ID: 38874949
[No Abstract] [Full Text] [Related]
3. Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs.
Jones JR; Barber A; Le Bihan YV; Weinhold N; Ashby C; Walker BA; Wardell CP; Wang H; Kaiser MF; Jackson GH; Davies FE; Chopra R; Morgan GJ; Pawlyn C
Leukemia; 2021 Oct; 35(10):3017-3020. PubMed ID: 34373585
[No Abstract] [Full Text] [Related]
4. Baricitinib Is First Approved COVID-19 Immunomodulatory Treatment.
Rubin R
JAMA; 2022 Jun; 327(23):2281. PubMed ID: 35727290
[No Abstract] [Full Text] [Related]
5. The Effect of Immunomodulatory Treatments on Anti-Dystrophin Immune Response After AAV Gene Therapy in Dystrophin Deficient mdx Mice.
Li N; Parkes JE; Spathis R; Morales M; Mcdonald J; Kendra RM; Ott EM; Brown KJ; Lawlor MW; Nagaraju K
J Neuromuscul Dis; 2021; 8(s2):S325-S340. PubMed ID: 34569971
[TBL] [Abstract][Full Text] [Related]
6. Vaccine considerations for adult dermatology patients on immunosuppressive and immunomodulatory therapies: a clinical review.
Tan AJ; Streicher JL; Merola JF; Noe MH
Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755974
[TBL] [Abstract][Full Text] [Related]
7. Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy.
Blanco B; Domínguez-Alonso C; Alvarez-Vallina L
Clin Cancer Res; 2021 Oct; 27(20):5457-5464. PubMed ID: 34108185
[TBL] [Abstract][Full Text] [Related]
8. The immunomodulatory effects of opioids and implications for intensive care unit populations.
Mefford B; Donaldson JC; Bissell BD
Pharmacotherapy; 2021 Aug; 41(8):668-675. PubMed ID: 34129683
[TBL] [Abstract][Full Text] [Related]
9. Treatment with immune modulators in a child with recent-onset type 1 narcolepsy.
Ding Q; Xiao F; Dong X; Zhang J; Han F
Sleep Breath; 2021 Mar; 25(1):387-389. PubMed ID: 32813213
[No Abstract] [Full Text] [Related]
10. [Clinical benefit of Tocilizumab and other immunomodulating agents for treatment of COVID-19].
Hornuss D; Giesen R; Biever P; Kern WV
Dtsch Med Wochenschr; 2021 Nov; 146(23):1538-1542. PubMed ID: 34826840
[TBL] [Abstract][Full Text] [Related]
11. Timing of Immunotherapy in Type 1 Diabetes: The Earlier, the Better?
Felton JL
Immunohorizons; 2021 Jul; 5(7):535-542. PubMed ID: 34261674
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targeting of inflammation in hypertension: from novel mechanisms to translational perspective.
Murray EC; Nosalski R; MacRitchie N; Tomaszewski M; Maffia P; Harrison DG; Guzik TJ
Cardiovasc Res; 2021 Nov; 117(13):2589-2609. PubMed ID: 34698811
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma.
Zanwar S; Ho M; Kapoor P; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Hayman SR; Dingli D; Kourelis T; Fonder A; Hobbs M; Hwa Y; Gonsalves W; Warsame R; Muchtar E; Leung N; Kyle RA; Rajkumar SV; Kumar S
Leukemia; 2022 Mar; 36(3):873-876. PubMed ID: 34635783
[No Abstract] [Full Text] [Related]
14. Choosing immunomodulating therapies for the treatment of COVID-19: recommendations based on placebo-controlled trial evidence.
Sweeney DA; Lobo SM; Póvoa P; Kalil AC
Clin Microbiol Infect; 2024 May; 30(5):611-618. PubMed ID: 38182048
[TBL] [Abstract][Full Text] [Related]
15. Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course.
Beran J; Špajdel M; Slíva J
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835052
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of Covid-19 Symptoms Among Inflammatory Bowel Disease Patients Treated with Biological Agents.
Conley TE; Probert C; Subramanian S
J Crohns Colitis; 2020 Dec; 14(12):1794-1795. PubMed ID: 32918090
[No Abstract] [Full Text] [Related]
17. Immunotherapy for cancer treatment during pregnancy.
Borgers JSW; Heimovaara JH; Cardonick E; Dierickx D; Lambertini M; Haanen JBAG; Amant F
Lancet Oncol; 2021 Dec; 22(12):e550-e561. PubMed ID: 34856152
[TBL] [Abstract][Full Text] [Related]
18. 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19.
Alunno A; Najm A; Machado PM; Bertheussen H; Burmester GR; Carubbi F; De Marco G; Giacomelli R; Hermine O; Isaacs JD; Koné-Paut I; Magro-Checa C; McInnes IB; Meroni PL; Quartuccio L; Ramanan AV; Ramos-Casals M; Rodríguez Carrio J; Schulze-Koops H; Stamm TA; Tas SW; Terrier B; McGonagle DG; Mariette X
Ann Rheum Dis; 2022 Jan; 81(1):34-40. PubMed ID: 34620584
[TBL] [Abstract][Full Text] [Related]
19. Role of IVIG in the Treatment of Autoimmune Conditions With Concurrent Immune Checkpoint Inhibitors for Metastatic Cancer.
Punekar SR; Castillo R; Sandigursky S; Cho DC
J Immunother; 2021 Oct; 44(8):335-337. PubMed ID: 34166301
[TBL] [Abstract][Full Text] [Related]
20. Cereblon enhancer methylation and IMiD resistance in multiple myeloma.
Haertle L; Barrio S; Munawar U; Han S; Zhou X; Vogt C; Fernández RA; Bittrich M; Ruiz-Heredia Y; Da Viá M; Zovko J; Garitano-Trojaola A; Bolli N; Ruckdeschel A; Stühmer T; Chatterjee M; Kull M; Krönke J; Agirre X; Martin-Subero JI; Raab P; Einsele H; Rasche L; Martinez-Lopez J; Haaf T; Kortüm KM
Blood; 2021 Nov; 138(18):1721-1726. PubMed ID: 34115836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
